Inhalerx Ltd Market Cap ($4.18 Million)
Market Cap & Net Worth: Inhalerx Ltd (IRX)
Inhalerx Ltd market cap. Inhalerx Ltd (AU:IRX) has a market capitalization of $4.18 Million (AU$5.91 Million) as of November 7, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28843 globally and #1545 in its home market, demonstrating a 33.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inhalerx Ltd's stock price AU$0.02 by its total outstanding shares 246257323 (246.26 Million). Also see how efficiently does Inhalerx Ltd generate cash for how efficiently the company converts equity into cash flow.
Inhalerx Ltd Market Cap History (2017–2026)
Inhalerx Ltd market cap history from 2017 to 2026. Data shows change from $23.68 Million to $4.18 Million (-25.92% CAGR). Check Inhalerx Ltd (IRX) stock price for real-time trading data and today's change.
Inhalerx Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inhalerx Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Inhalerx Ltd (IRX) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
18.20x
Inhalerx Ltd's market cap is 18.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $23.68 Million | $493.31K | -$2.10 Million | 48.00x | N/A |
| 2018 | $10.14 Million | $345.79K | -$1.87 Million | 29.33x | N/A |
| 2019 | $5.75 Million | $46.60K | -$2.39 Million | 123.39x | N/A |
| 2020 | $13.42 Million | $97.50K | -$1.01 Million | 137.61x | N/A |
| 2021 | $15.68 Million | $167.30K | -$1.11 Million | 93.73x | N/A |
| 2022 | $10.45 Million | $24.80K | -$1.93 Million | 421.56x | N/A |
| 2023 | $5.05 Million | $1.20 Million | -$1.44 Million | 4.20x | N/A |
| 2024 | $6.10 Million | $335.10K | -$1.28 Million | 18.20x | N/A |
Competitor Companies of IRX by Market Capitalization
Companies near Inhalerx Ltd in the global market cap rankings as of November 7, 2026. Also see Inhalerx Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Inhalerx Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Inhalerx Ltd (2017–2026)
Market capitalization of Inhalerx Ltd from 2017 to today. Between 2017 and today, Inhalerx Ltd's market cap moved from $23.68 Million to $ 4.18 Million, with a yearly change of -25.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$4.18 Million | 0.00% |
| 2025 | AU$4.18 Million | -31.43% |
| 2024 | AU$6.10 Million | +20.69% |
| 2023 | AU$5.05 Million | -51.67% |
| 2022 | AU$10.45 Million | -33.33% |
| 2021 | AU$15.68 Million | +16.88% |
| 2020 | AU$13.42 Million | +133.33% |
| 2019 | AU$5.75 Million | -43.30% |
| 2018 | AU$10.14 Million | -57.17% |
| 2017 | AU$23.68 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Inhalerx Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.18 Million USD |
| MoneyControl | $4.18 Million USD |
| MarketWatch | $4.18 Million USD |
| marketcap.company | $4.18 Million USD |
| Reuters | $4.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inhalerx Ltd
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexali… Read more